Hjem › Eggstokkreft › Oregon
Kliniske studier for Eggstokkreft i Oregon
34 studier for Eggstokkreft søker deltakere på steder i Oregon.
Byer i Oregon
Offisiell studietekst (engelsk)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- og 1 flere
RekruttererFase 2
Alle aldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT05564377The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Oregon Health & Science University (OHSU), Portland
RekruttererFase 1/2
Alder 12 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT04585750A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
- Providence Portland Medical Center /ID# 277727, Portland
RekruttererFase 2
Alder 18 og eldre · Kvinner · Oppdatert 1. okt. 2026 · NCT07024784A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
- Site 02, Portland
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 30. sep. 2026 · NCT07814248A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
- Research Site, Portland
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 29. sep. 2026 · NCT05877599A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Site 0316 - Willamette Valley Cancer Institute/Oncology Associates of Oregon, Eugene
RekruttererFase 2
Alder 18 og eldre · Kvinner · Oppdatert 29. sep. 2026 · NCT05128825A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
- Oncology Associates of Oregon, P.C. /ID# 275006, Eugene
- Compass Oncology - West - Tigard /ID# 275101, Tigard
RekruttererFase 2
Alder 18 og eldre · Kvinner · Oppdatert 29. sep. 2026 · NCT06890338Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, Portland
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT05867251A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
- Willamette Valley Cancer Institute and Research Center /ID# 277714, Eugene
RekruttererFase 2
Alder 18 og eldre · Kvinner · Oppdatert 22. sep. 2026 · NCT07059845A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- USO - Oncology Associates of Oregon, P. C., Eugene
- Providence Portland Medical Center, Portland
- Kaiser Permanente Interstate Medical Office Central, Portland
- og 1 flere
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT07213804Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
- Providence Cancer Institute, Portland
RekruttererFase 3
Alder 18 og eldre · Kvinner · Oppdatert 15. sep. 2026 · NCT06915025Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Oncology Associates of Oregon, P.C., Eugene
- Providence Cancer Institute Franz Clinic, Portland
RekruttererFase 3
Alder 18 og eldre · Kvinner · Oppdatert 15. sep. 2026 · NCT07214779FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
- Asante / Heimann Cancer Center, Medford
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 14. sep. 2026 · NCT06303505Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
- Providence Cancer Institute, Portland
RekruttererFase 2
Alder 18 og eldre · Kvinner · Oppdatert 14. sep. 2026 · NCT06787612Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Providence Portland Medical Center, Portland
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 10. sep. 2026 · NCT06293898A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) ( Site 8010), Eugene
RekruttererFase 3
Alder 18 og eldre · Kvinner · Oppdatert 3. sep. 2026 · NCT06824467Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
- Research Site, Portland
RekruttererFase 1/2
Alder 18 til 130 · Alle kjønn · Oppdatert 21. aug. 2026 · NCT05797168Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
- Oregon Health and Science University, Portland
RekruttererFase 2/3
Alder 18 og eldre · Alle kjønn · Oppdatert 19. aug. 2026 · NCT07001748A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
- Providence Cancer Center Oncology and Hematology Care- Eastside, Portland
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 17. aug. 2026 · NCT04895709A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
- Site 0105, Portland
RekruttererFase 3
Alder 18 og eldre · Kvinner · Oppdatert 12. aug. 2026 · NCT07546500A Study of MGC026 in Participants With Advanced Solid Tumors
- Providence Cancer Institute, Portland
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 11. aug. 2026 · NCT06242470A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- Saint Charles Health System, Bend
- Clackamas Radiation Oncology Center, Clackamas
- Bay Area Hospital, Coos Bay
- og 9 flere
Rekrutterer
Alder 35 til 50 · Kvinner · Oppdatert 7. aug. 2026 · NCT04251052Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- Saint Alphonsus Cancer Care Center-Baker City, Baker City
- Saint Charles Health System, Bend
- Clackamas Radiation Oncology Center, Clackamas
- og 11 flere
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 7. aug. 2026 · NCT06580314Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR Oncology Associates of Oregon, P.C., Eugene
- Compass Oncology - Rose Quarter, Portland
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 4. aug. 2026 · NCT05579366A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Oregon Health & Science University, Portland
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 30. jul. 2026 · NCT04657068A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Oncology Associates of Oregon, P.C., Eugene
RekruttererFase 2/3
Alder 18 og eldre · Alle kjønn · Oppdatert 28. jul. 2026 · NCT06161025Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
- 517, Eugene
RekruttererFase 2
Alder 18 og eldre · Kvinner · Oppdatert 16. jul. 2026 · NCT06906341First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- Providence Cancer Institute Franz Clinic, Portland
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 7. jul. 2026 · NCT05768139A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- Providence Cancer Institute Franz Clinic, Portland
- Providence Oncology and Hematology Care Clinic - Westside, Portland
- Providence St. Vincent Medical Center- Investigational Drug Services, Portland
- og 1 flere
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 6. jul. 2026 · NCT04389632Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- Legacy Medical Group Gynecologic Oncology, Portland
- Providence Cancer Center Oncology, Portland
RekruttererFase 3
Alder 18 og eldre · Kvinner · Oppdatert 2. jul. 2026 · NCT06819007DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- USA15-0, Portland
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 22. mai 2026 · NCT06953089cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Oregon Health Sciences University, Portland
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alder 40 og eldre · Alle kjønn · Oppdatert 20. jan. 2026 · NCT05366881CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
- SCRI - Northwest Cancer Specialists, P.C., Portland
RekruttererFase 2
Alder 18 og eldre · Kvinner · Oppdatert 23. des. 2025 · NCT06690775SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Portland
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 28. okt. 2025 · NCT03452774Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.